Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 5/20 | 0.60 |
| ▸ | IMPDH1 | P20839 | 3/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8347880 | 0.81 | IMPDH2 (0.62) | IMPDH2IMPDH1MAP4K4PTK2NOTUM | |
| SCHEMBL6168364 | 0.79 | IMPDH2 (0.65) | IMPDH2IMPDH1MAP4K4PTK2NOTUM | |
| SCHEMBL5780722 | 0.79 | IMPDH2 (0.60) | IMPDH2IMPDH1MAP4K4PTK2NOTUM | |
| SCHEMBL6170749 | 0.79 | IMPDH2 (0.60) | IMPDH2IMPDH1MAP4K4PTK2NOTUM | |
| SCHEMBL6169923 | 0.79 | IMPDH2 (0.60) | IMPDH2IMPDH1MAP4K4PTK2NOTUM | |
| SCHEMBL29454983 | 0.79 | IMPDH2 (0.60) | IMPDH2IMPDH1MAP4K4PTK2NOTUM | |
| SCHEMBL5777545 | 0.79 | IMPDH2 (0.42) | IMPDH2IMPDH1MAP4K4AAK1 | |
| SCHEMBL12907859 | 0.76 | IMPDH2 (0.60) | IMPDH2IMPDH1MAP4K4PTK2NOTUM | |
| SCHEMBL16238614 | 0.76 | IMPDH2 (0.56) | IMPDH2IMPDH1MAP4K4PTK2NOTUM | |
| SCHEMBL926045 | 0.76 | IMPDH2 (0.56) | IMPDH2IMPDH1MAP4K4PTK2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | IMPDH2 4694/4885IMPDH1 4461/4885MAP4K4 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.